Simon F. Roy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simon F. Roy has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Marcus W. Bosenberg
Department of Pathology, Yale School of Medicine, New Haven, Connecticut
27 shared publications - Goran Micevic
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
17 shared publications - Andrew J. Daniels
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
15 shared publications - Karine Flem-Karlsen
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
15 shared publications - Koonam Park
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
15 shared publications - Meaghan K. McGeary
Department of Pathology, Yale School of Medicine, New Haven, Connecticut
15 shared publications
Latest Publications
- 12 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Launching an independent research laboratory and scientific career: Tools for a rapidly changing landscape
Scientific independence alone does not create a sustainable research program. Drawing on the 2026 Irving Cancer Immunology Symposium, we offer practical strategies for navigating uncertainty and limited resources to build a coherent research program and resilient team across funding systems.
- 12 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Launching an independent research laboratory and scientific career: Tools for a rapidly changing landscape
Scientific independence alone does not create a sustainable research program. Drawing on the 2026 Irving Cancer Immunology Symposium, we offer practical strategies for navigating uncertainty and limited resources to build a coherent research program and resilient team across funding systems.
- Open Access
Spitz tumours with MET gene fusions: 17 cases with identifiable histomorphological and genetic features
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade
DepMap HMGCR gene expression and gene effect scores for 1,078 cancer cell lines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade
DepMap HMGCR gene expression and gene effect scores for 1,078 cancer cell lines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade
Mevalonate pathway activity distinguishes treatment response in melanoma tumor cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade
Mevalonate pathway activity distinguishes treatment response in melanoma tumor cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade
Statins have been reported to exert anticancer activity, varying with cancer type and specific statins. These findings suggest that more mechanistic insights into the anticancer effects of statins are needed. In this study, we interrogated the ability of statins to induce cell death and ferroptosis in melanoma and colorectal cancer. First, we showed that statins induce cell death in patient-derived melanoma cell lines and that lower expression of mevalonate pathway genes correlates with increased CD8+ T-cell infiltration and improved overall survival in patients with melanoma. We found that lipophilic statins induce cell death with features of ferroptosis. Transcriptional data also revealed system-level changes to a variety of ferroptosis-related pathways. We found that mevalonate rescued statin-induced cell death. Mechanistically, mevalonate-derived isopentyl pyrophosphate is necessary for isopentylation of tRNA [Ser]Sec, which is required for efficient synthesis of the selenoprotein ferroptosis suppressor GPX4. Given the emerging role for ferroptosis in antitumor immunity, we tested lipophilic statins, including simvastatin, alone and in combination with α-PD1 in vivo and found that simvastatin and α-PD1 promoted tumor clearance and extended survival in 20% to 60% of mice alone but in nearly 100% of mice when administered together. Simvastatin also depleted GPX4 in vivo. These results highlight the therapeutic potential of statin use in combination with immunotherapies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade
Statins have been reported to exert anticancer activity, varying with cancer type and specific statins. These findings suggest that more mechanistic insights into the anticancer effects of statins are needed. In this study, we interrogated the ability of statins to induce cell death and ferroptosis in melanoma and colorectal cancer. First, we showed that statins induce cell death in patient-derived melanoma cell lines and that lower expression of mevalonate pathway genes correlates with increased CD8+ T-cell infiltration and improved overall survival in patients with melanoma. We found that lipophilic statins induce cell death with features of ferroptosis. Transcriptional data also revealed system-level changes to a variety of ferroptosis-related pathways. We found that mevalonate rescued statin-induced cell death. Mechanistically, mevalonate-derived isopentyl pyrophosphate is necessary for isopentylation of tRNA [Ser]Sec, which is required for efficient synthesis of the selenoprotein ferroptosis suppressor GPX4. Given the emerging role for ferroptosis in antitumor immunity, we tested lipophilic statins, including simvastatin, alone and in combination with α-PD1 in vivo and found that simvastatin and α-PD1 promoted tumor clearance and extended survival in 20% to 60% of mice alone but in nearly 100% of mice when administered together. Simvastatin also depleted GPX4 in vivo. These results highlight the therapeutic potential of statin use in combination with immunotherapies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade
Statins suppress GPX4 expression and mevalonate rescues statin-induced cell death
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade
Statins suppress GPX4 expression and mevalonate rescues statin-induced cell death